Media coverage about Invuity (NASDAQ:IVTY) has been trending positive recently, Accern Sentiment Analysis reports. The research firm identifies negative and positive press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Invuity earned a coverage optimism score of 0.29 on Accern’s scale. Accern also assigned news articles about the medical instruments supplier an impact score of 46.9613202004449 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Here are some of the media stories that may have effected Accern’s analysis:
A number of equities analysts recently issued reports on the stock. Piper Jaffray Companies reaffirmed a “buy” rating and set a $12.00 target price on shares of Invuity in a research report on Friday, November 10th. Northland Securities reaffirmed a “buy” rating and set a $6.00 target price on shares of Invuity in a research report on Wednesday. Finally, Zacks Investment Research lowered shares of Invuity from a “buy” rating to a “hold” rating in a research report on Tuesday, January 30th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $8.50.
Shares of Invuity (NASDAQ IVTY) traded up $0.05 during mid-day trading on Friday, reaching $4.15. 158,190 shares of the company were exchanged, compared to its average volume of 314,024. Invuity has a fifty-two week low of $3.70 and a fifty-two week high of $9.70. The company has a market capitalization of $71.29, a price-to-earnings ratio of -1.77 and a beta of -0.50. The company has a debt-to-equity ratio of 5.39, a current ratio of 2.90 and a quick ratio of 2.47.
Invuity (NASDAQ:IVTY) last announced its earnings results on Tuesday, February 13th. The medical instruments supplier reported ($0.43) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.50) by $0.07. Invuity had a negative net margin of 100.75% and a negative return on equity of 279.04%. The business had revenue of $11.23 million for the quarter, compared to analyst estimates of $11.84 million. equities analysts anticipate that Invuity will post -1.88 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Invuity (IVTY) Earns News Sentiment Score of 0.29” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another site, it was stolen and reposted in violation of international copyright legislation. The legal version of this piece can be viewed at https://www.dispatchtribunal.com/2018/02/18/invuity-ivty-earns-news-sentiment-score-of-0-29.html.
Invuity Company Profile
Invuity, Inc, a medical technology company, develops various surgical devices to address various surgical procedures in the United States. The company integrates its intelligent photonics technology platform into its single-use and reusable advanced surgical devices to address various critical intracavity illumination and visualization challenges.
Receive News & Ratings for Invuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invuity and related companies with MarketBeat.com's FREE daily email newsletter.